$OTLK

Outlook Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$1.21 β–²1.681%

Extented Hours

VOLUME

284,632

DAY RANGE

1.175 - 1.27

52 WEEK

0.6839 - 2.87

Join Discuss about OTLK with like-minded investors

profile
@Math #StockTraders.NET
recently

$OTLK what a bleed

97 Replies 14 πŸ‘ 7 πŸ”₯

profile
@maletone #StockTraders.NET
recently

covered $OTLK to early 😁

126 Replies 7 πŸ‘ 12 πŸ”₯

profile
@maletone #StockTraders.NET
recently

all covered $OTLK

125 Replies 15 πŸ‘ 8 πŸ”₯

profile
@Chano #StockTraders.NET
recently

fantastic trade bro > @maletone said: coverd some $OTLK 2.61 have 1/3rd left

47 Replies 13 πŸ‘ 14 πŸ”₯

profile
@maletone #StockTraders.NET
recently

coverd some $OTLK 2.61 have 1/3rd left

136 Replies 15 πŸ‘ 11 πŸ”₯

profile
@maletone #StockTraders.NET
recently

got covers out on $OTLK here

41 Replies 12 πŸ‘ 15 πŸ”₯

profile
@maletone #StockTraders.NET
recently

ok $OTLK still going the ATM machine doesn't stop for no one

114 Replies 14 πŸ‘ 12 πŸ”₯

profile
@maletone #StockTraders.NET
recently

$OTLK price target raised to $6 at HC WAINWright --- Strong NORSE TWO Topline Should Pave the Way for Approva

120 Replies 15 πŸ‘ 15 πŸ”₯

profile
@maletone #StockTraders.NET
recently

could have caught $EJH and $OTLK better

88 Replies 7 πŸ‘ 13 πŸ”₯

profile
@Chano #StockTraders.NET
recently

yup, pure sorcery, $OTLK also hit the VWAP blvd wall premarket and never got back to test it > @TraderXx said: the power of VWAP BLVD is unmatched

94 Replies 6 πŸ‘ 11 πŸ”₯

WI
@WINTERTRADE #StockTraders.NET
recently

i will be there on pops $otlk

40 Replies 6 πŸ‘ 6 πŸ”₯

profile
@maletone #StockTraders.NET
recently

i'm watching $OTLK for pops

45 Replies 11 πŸ‘ 15 πŸ”₯

profile
@maletone #StockTraders.NET
recently

https://www.floatchecker.com/stock?float=otlk

95 Replies 11 πŸ‘ 8 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$OTLK appears to be approx 8M floater

52 Replies 13 πŸ‘ 7 πŸ”₯

WI
@WINTERTRADE #StockTraders.NET
recently

$otlk nice fail

133 Replies 13 πŸ‘ 6 πŸ”₯

AN
@andres168 #StockTraders.NET
recently

main will be $otlk for me

44 Replies 7 πŸ‘ 11 πŸ”₯

WI
@WINTERTRADE #StockTraders.NET
recently

$nete $evk $dlpn $otlk $hjli

118 Replies 8 πŸ‘ 7 πŸ”₯

profile
@TraderXx #StockTraders.NET
recently

$OTLK BLVD's at 3 and 3.50

72 Replies 12 πŸ‘ 7 πŸ”₯

SO
@soheil.n #StockTraders.NET
recently

$OTLK - Feb 9th blvd 3.43....3.5 would be of interest (whole/half #)

119 Replies 12 πŸ‘ 14 πŸ”₯

profile
@maletone #StockTraders.NET
recently

hopefully $OTLK pushes out higher

135 Replies 11 πŸ‘ 7 πŸ”₯

profile
@viking #StockTraders.NET
recently

Upside: -ENOB +159% (announces FDA Acceptance of Pre-IND Request for Potential HIV Cure) -ITOS +51% (GSK and iTeos announce development and commercialisation collaboration for EOS-448) -CRSR +15% (hearing interest from WallStreetBets) -NVAX +9.0% (COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial) -LPCN +8.3% (FDA clears LPCN 1154 IND application for a Phase 2 Postpartum Depression Study) -RIOT +8.3% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -HAPP +7.8% (signed agreement to distribute Volkswagen Electric Vehicles) -MARA +7.8% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -RAPT +7.7% (reports positive topline results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis) -AMTX +6.0% (signs $200M biofuels offtake agreement with international renewable fuels supplier Murex, LLC to be delivered during 2021 to 2023) -OCC +5.4% (earnings) -EFOI +4.8% (enters marketing partnership with FirstEnergy Home and FirstEnergy Advisors) -TWST +3.2% (collaborates with Regeneron for production of genotyping by sequencing panel to enable diverse genome-wide screening) -HGEN +2.8% (initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)) -CODA +2.3% (earnings) -OTLK +2.3% (announces inclusion in the Russell 2000 Index, effective June 25, 2021) -SVOK +1.1% (confirms Boxed to go public through merger with Seven Oaks Acquisition Corp. in deal valued at ~$900M) Downside: -ATXI -47% (receives Complete Response Letter from the FDA for IV Tramadol, saying it does not support benefits as a monotherapy) -RIDE -11% (CEO and CFO resign following results of special committee investigation of Hindenburg Research report) -HEXO -3.6% (earnings) -NKLA -1.5% (discloses entered into a purchase agreement and a registration rights agreement with Tumim Stone Capital to sell $300M of the Nikola's common stock)

106 Replies 8 πŸ‘ 9 πŸ”₯

profile
@viking #StockTraders.NET
recently

Upside: -CYCN +16% (announces Global Licensing agreement with Akebia Therapeutics for Praliciguat; eligible to receive up to $585M in milestone payments) -SFIX +12% (earnings, guidance) -REVG +10% (earnings, guidance) -CHS +9.9% (earnings, guidance) -EVOK +8.4% (announces FDA Orange Book Listing of U.S. Patent for Gimoti) -ASO +7.2% (earnings, guidance) -MCF +6.6% (to be acquired by Independence Energy in all stock transaction valued at ~$5.7B) -JILL +6.3% (earnings, guidance) -MRVL +5.6% (earnings, guidance) -BYSI +4.8% (announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data) -THO +4.1% (earnings) -STX +3.7% (raises guidance) -TSLA +2.9% (strong China May passenger vehicle sales) -INO +2.6% (expands partnership with Advaccine to conduct global Phase III efficacy trial of COVID-19 DNA vaccine candidate, INO-4800) -OTLK +2.3% (reports completion of patient dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial) -FTCI +1.4% (earnings, guidance; raising prices) -LUV +1.2% (guidance) Downside: -PLBY -10% (files to offer 4.0M shares) -COUP -8.9% (earnings, guidance; Tony Tiscornia promoted to CFO) -TIGR -7.6% (files to sell 6.5M ADS) -HSTO -7.5% (announces 6.0M share direct offering priced at $1.10/shr) -LESL -5.7% (to sell 24.5M shares for holders) -HQY -5.5% (earnings, guidance) -KDP -4.9% (files to sell 28M common share secondary offering on behalf of Mondelez International) -FTCI -4.7% (earnings, guidance; raising prices) -FSLY -1.7% (hearing Fastly edge CDN platform is having issues causing internet outages) -ETSY -1.3% (files proposed private offering of $1.0B of convertible senior notes) -WBA -1.3% (AMZN reportedly to offer discounted pharmacy services targeting uninsured and those paying cash)

92 Replies 6 πŸ‘ 9 πŸ”₯

RH
@Rhodes117 #WallStreetBets
recently

I still say $OTLK to the moon... it's been rising quite well and if enough people jump on it, there are profits to be made

150 Replies 10 πŸ‘ 8 πŸ”₯

RH
@Rhodes117 #WallStreetBets
recently

OTLK looks like it's taking a small dip but other than that, it's been going up

90 Replies 7 πŸ‘ 7 πŸ”₯

Key Metrics

Market Cap

275.65 M

Beta

1.40

Avg. Volume

478.66 K

Shares Outstanding

225.94 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-12

Next Dividend Date

Company Information

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVAβ„’ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.

CEO: Lawrence Kenyon

Website:

HQ: 485 Route 1 South Iselin, 08830 New Jersey

Related News